Sentinel Node Biopsy in Patients With Breast Carcinoma Without Axillary Involvement at Diagnosis Receiving Primary Systemic Therapy

被引:0
|
作者
Garcia-Calvo, Laura [1 ]
Alvarez, Covadonga Marti [2 ]
Gutierrez, Alicia Hernandez [3 ,4 ,5 ]
Garcia, Alberto Berjon [6 ]
Munoz, Rocio Arnedo [7 ]
Sanchez-Mendez, Jose I. [2 ,3 ,4 ]
机构
[1] Campo Grande Hosp, Dept Gynecol & Obstet, Breast Pathol Unit, Valladolid 47002, Spain
[2] La Paz Univ Hosp, Dept Gynecol & Obstet, Breast Pathol Unit, Madrid, Spain
[3] Univ Autonoma Dept, Madrid, Spain
[4] Hosp La Paz, Inst Hlth Res IdiPAZ, Madrid, Spain
[5] La Paz Univ Hosp, Gynecol & Obstet Dept, Gynecol Oncol Unit, Madrid, Spain
[6] La Paz Univ Hosp, Pathol Anat Dept, Madrid, Spain
[7] Rey Juan Carlos Univ Hosp, Gynecol & Obstet Dept, Madrid, Spain
关键词
Axillary dissection; Breast cancer; Neoadjuvant chemotherapy; Sentinel lymph node dissection; NEOADJUVANT CHEMOTHERAPY; CANCER; SURGERY; PROVEN;
D O I
10.1016/j.clbc.2023.05.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this work is to try to elucidate the optimal time to perform SLNB in cN0 patients with BC. At the moment we do not have randomized trials that answer this question. With the current criteria for performing ALND after NAC, we have concluded that we benefit patients with Luminal phenotype if we perform SLNB prior to NAC.Background: Primary systemic therapy (PST) has acquired great importance in breast cancer (BC) in the last few years. In this scenario, even if it is accepted to perform SLNB before PST, most of the guidelines remark the advantages of this practice after it, such as avoiding another surgery to the patient, a rapid start of the treatment and no need of axillary dissection in cases of pathologic complete response (pCR). Nevertheless, the lack of knowledge of the initial axillary state and the need to practice axillary dissection with any axillary disease are claimed to be some other disadvantages. There are no randomized studies yet that can conclude the optimal timing of SLNB in PST, so for the moment we may settle for our common practice. Patients and Methods: We studied all the cases attended in the Breast Unit that joined the inclusion criteria between 2011 and 2019 in our hospital and we compared the group with SLNB before PST with the group with SLNB after PST in terms of unnecessary axillary dissection and description features. Results: We included 223 female patients diagnosed with BC and without clinical nor radiological axillary disease (cN0), who had received NAC and SLNB performed before or after it. We observed a higher proportion of high-grade histological tumors (G3), tumors with aggressive phenotypes (Basal like and Her 2 enriched), and younger women in the group of SLNB before NAC compared with the SLNB after NAC group ( P < .01). Despite this, we did not find any difference in the number of positive SLNBs or in the number of ALND performed between the 2 groups. We found a higher proportion of ALND with all the lymph node (LN) negatives in the SLNB before NAC group. Conclusion: Taking into account that in the observation period we did not use ACOSOG Z0011 criteria with all the SLNBs, we figure out what would have been the real results nowadays following these criteria. In this scenario we conclude that patients with luminal phenotype seemed to benefit from practicing SLNB before NAC in terms of avoiding axillary dissections. We could not make any conclusion in the rest of the phenotypes. However, prospective studies are needed to confirm if this affirmation could be proved.
引用
收藏
页码:672 / 679
页数:8
相关论文
共 50 条
  • [31] Axillary lymph node dissection in breast cancer patients after sentinel node biopsy
    Jessing, Christina
    Langhans, Linnea
    Jensen, Maj-Britt
    Talman, Maj-Lis
    Tvedskov, Tove Filtenborg
    Kroman, Niels
    ACTA ONCOLOGICA, 2018, 57 (01) : 166 - 169
  • [32] Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach
    Damin, Andrea P.
    Zancan, Maira
    Melo, Marcia P.
    Biazus, Jorge V.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (02) : 527 - 534
  • [33] Sentinel lymph-node biopsy compared to axillary lymph-node dissection for axillary staging in breast cancer patients
    Schrenk, P
    Shamiyeh, A
    Wayand, W
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2001, 27 (04): : 378 - 382
  • [34] Sentinel lymph node biopsy after neoadjuvant systemic chemotherapy in patients with breast cancer: a prospective pilot trial
    Medina-Franco, Heriberto
    Salgado-Nesme, Noel
    Zeron-Medina-Cuairan, Jorge
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2008, 60 (05): : 390 - 394
  • [35] Sentinel lymph node biopsy alone without axillary lymph node dissection - follow up of sentinel lymph node negative breast cancer patients
    Reitsamer, R
    Peintinger, F
    Prokop, E
    Menzel, C
    Cimpoca, W
    Rettenbacher, L
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2003, 29 (03): : 221 - 223
  • [36] Sentinel lymph node biopsy and neoadjuvant chemotherapy in breast cancer patients
    Benson, John R.
    Jatoi, Ismail
    FUTURE ONCOLOGY, 2014, 10 (04) : 577 - 586
  • [37] Recurrence after sentinel lymph node biopsy with or without axillary lymph node dissection in patients with breast cancer.
    Takei H.
    Suemasu K.
    Kurosumi M.
    Horii Y.
    Yoshida T.
    Ninomiya J.
    Yoshida M.
    Hagiwara Y.
    Kamimura M.
    Hayashi Y.
    Inoue K.
    Tabei T.
    Breast Cancer, 2007, 14 (1) : 16 - 24
  • [38] Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype
    Di Micco, Rosa
    Zuber, Veronica
    Fiacco, Enrico
    Carriero, Federica
    Gattuso, M. Ilaria
    Nazzaro, Ludovica
    Panizza, Pietro
    Gianolli, Luigi
    Canevari, Carla
    Di Muzio, Nadia
    Pasetti, Marcella
    Sassi, Isabella
    Zambetti, Milvia
    Gentilini, Oreste D.
    EJSO, 2019, 45 (06): : 969 - 975
  • [39] Outcomes of Sentinel Lymph Node Biopsy for Patients With Node-positive Breast Cancer Treated With Neoadjuvant Chemotherapy
    Cipolla, Calogero
    Vieni, Salvatore
    D'agati, Eleonora
    Grassi, Nello
    Genova, Pietro
    Graceffa, Giuseppa
    Vigneri, Paolo
    Gebbia, Vittorio
    Valerio, Maria rosaria
    ANTICANCER RESEARCH, 2023, 43 (10) : 4643 - 4649
  • [40] Can we avoid axillary lymph node dissection in patients with node positive invasive breast carcinoma?
    Brousse, Susie
    Lafond, Clementine
    Schmitt, Martin
    Guillermet, Sophie
    Moliere, Sebastien
    Mathelin, Carole
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2024, 52 (03): : 132 - 141